Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HYPD with free AI briefings, catalyst countdowns, and dilution alerts.

HYPD · HYPERION DEFI, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 8.7 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed May 6, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$6.6M Cash on Hand
8.7mo Cash Runway
Follow HYPD by email Get an email when HYPD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HYPD, unsubscribe in one click. Privacy

📣 What HYPD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

HYPD holds $6.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.3M/quarter from operations, an estimated runway of 8.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HYPD files for a raise →

👥 Who Owns HYPD

Insiders 15.2% Institutions (42 holders) 19.6% Public and other holders 65.2%
HolderTypeShares% of sharesAs of
Hyunsu Jung
Chief Executive Officer and Chief Invest
Insider 1,345,676 8.69% 2026-08-16
David R. Knox
Chief Financial Officer
Insider 287,556 1.86% 2026-09-29
Happy David Walters
Director
Insider 170,847 1.10% 2026-06-30
Ellen R Strahlman
Director
Insider 150,078 0.97% 2026-06-30
Michael S Geltzeiler
Director
Insider 146,932 0.95% 2026-06-30
Rachel Jacobson
Director
Insider 115,218 0.74% 2026-06-30
Robert Rubenstein
General Counsel
Insider 75,000 0.48% 2026-01-12
Avenue Capital Management II, L.P.
10% owner
Insider 30,619 0.20% 2025-02-21
Tsontcho Ianchulev
Director
Insider 17,780 0.11% 2025-04-21
Charles E Iv Mather
Director
Insider 9,950 0.06% 2025-04-21
Michael M Rowe
Chief Executive Officer, Director
Insider 7,975 0.05% 2025-06-13
Ram Palanki
Director
Insider 4,235 0.03% 2025-04-21

Share count 15,488,133 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HYPD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HYPD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.